In recent stock market activity, GE HealthCare Techs (GEHC, Financial) has received a noteworthy update from UBS analyst Graham Doyle. The analyst has upgraded the stock's rating from "Sell" to "Neutral." This change in rating signifies a shift in the analyst's outlook on the performance of GEHC.
Despite the upgrade in rating, the price target for GEHC has been adjusted downward. The current price target has been set at USD 73.00, which is a decrease from the previous target of USD 74.00. This adjustment represents a percentage change of -1.35%.
The decision by Graham Doyle to lower the price target reflects a more cautious approach towards the stock's valuation, even as the overall rating sees an improvement. Investors in GEHC may find this mixed signal of interest as they consider their investment strategies.
The updates provided by UBS on May 5, 2025, are part of regular analyst assessments that can influence market sentiment and investor decisions regarding GE HealthCare Techs (GEHC, Financial).
Wall Street Analysts Forecast
Based on the one-year price targets offered by 18 analysts, the average target price for GE HealthCare Technologies Inc (GEHC, Financial) is $89.03 with a high estimate of $106.00 and a low estimate of $74.00. The average target implies an upside of 27.13% from the current price of $70.03. More detailed estimate data can be found on the GE HealthCare Technologies Inc (GEHC) Forecast page.
Based on the consensus recommendation from 19 brokerage firms, GE HealthCare Technologies Inc's (GEHC, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
